We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

That's the way, uh huh

17 Mar 2011 By Chris Hughes

The NY hedge fund is dead serious in demanding Actelion launches a strategic review and has assembled a slate of directors to storm the Swiss biotech’s board. In defence, the $7.8 bln firm hired Goldman and Credit Suisse. Elliott’s battle could be protracted but looks winnable.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)